Nyxoah Reports Third Quarter 2023 Financial and Operating Results

Nyxoah Reports Third Quarter 2023 Financial and Operating Results
Partners with ResMed Germany to increase OSA awareness and therapy penetration

Mont-Saint-Guibert, Belgium – November 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the third quarter of 2023.
Recent Financial and Operating Highlights

  • Filed the third module in the modular PMA submission.
  • Accelerated U.S. pre-commercialization efforts, focused on market access around CPT coding.
  • Initiated a commercial partnership with strategic investor ResMed in Germany. This collaboration introduces a novel continuum of care into the German OSA market.
  • Reported third-quarter sales of €1.0 million and ended the quarter with 46 active German accounts.
  • Ended the quarter with a cash position of €72.5 million, providing an anticipated cash runway into late 2024.

“Nyxoah is entering one of the most exciting times in the company’s history. We will report data from our DREAM U.S. pivotal trial early next year, shortly thereafter complete our modular PMA submission, and expect FDA approval late 2024,” commented Olivier Taelman, Chief Executive Officer. “Hypoglossal nerve stimulation (HGNS) remains highly underpenetrated and guiding patients through their OSA journey is key to unlocking the market’s potential. Our agreement with ResMed Germany, which takes ResMed from a valued investor to commercial partner, creates a continuum of care that directs patients towards the appropriate treatment, resulting in greater therapy penetration.”    


 (in thousands)

   For the three months ended September 30For the nine months ended September 30
   2023 2022 20232022
Revenue  € 976 € 182 € 2,524 € 1,777
Cost of goods sold  ( 336) ( 63) ( 930) ( 685)
Gross profit  € 640 € 119 € 1,594 € 1,092
Research and Development Expense  (6,568) (4,221) (19,330) (11,286)
Selling, General and Administrative Expense  (5,058) (4,763) (16,794) (13,492)
Other income/(expense)   87 265 237
Operating loss for the period  € (10,986) € (8,778) € (34,265) € (23,449)
Financial income  2,178 5,127 3,592 11,372
Financial expense  (1,033) (2,524) (2 765) (5,473)
Loss for the period before taxes  € (9,841) € (6,175) € (33,438) € (17,550)
Income taxes  2,229 (65) 1,119 ( 379)
Loss for the period  € (7,612) € (6,240) € (32,319) € (17,929)
Loss attributable to equity holders  € (7,612) € (6,240) € (32,319) € (17,929)
Other comprehensive loss         
Items that may be subsequently reclassified to profit or loss (net of tax)         
Currency translation differences  ( 10) 100 ( 88) ( 14)
Total comprehensive loss for the year, net of tax  € (7,622) € (6,140) € (32,407) € (17,943)
Loss attributable to equity holders  € (7,622) € (6,140) € (32,407) € (17,943)
Basic Loss Per Share (in EUR)  € (0.266) € (0.242) € (1.166) € (0.695)
Diluted Loss Per Share (in EUR)  € (0.266) € (0.242) € (1.166) € (0.695)


(in thousands)
   As at 
   September 30
 December 31 2022 
Non-current assets      
Property, plant and equipment  4,328 2,460 
Intangible assets  45,720 39,972 
Right of use assets  3,602 3,159 
Deferred tax asset  47 47 
Other long-term receivables  668 173 
   € 54,365 € 45,811 
Current assets      
Inventory  1,709 882 
Trade receivables  1,918 1,463 
Other receivables  2,437 1,775 
Other current assets  1,683 1,284 
Financial assets  59,239 76,968 
Cash and cash equivalents  13,250 17,888 
   € 80,236 € 100,260 
Total assets  € 134,601 € 146,071 
Capital and reserves      
Capital  4,926 4,440 
Share premium  246,130 228,275 
Share based payment reserve  7,468 5,645 
Other comprehensive income  88 176 
Retained loss  (150,070) (118,212) 
Total equity attributable to shareholders  € 108,542 € 120,324 
Non-current liabilities      
Financial debt  8,407 8,189 
Lease liability  2,990 2,586 
Pension liability  75  
Provisions  125 59 
Deferred tax liability  6  
   € 11,603 € 10,834 
Current liabilities      
Financial debt  769 388 
Lease liability  788 719 
Trade payables  4,480 4,985 
Current tax liability  2,367 3,654 
Other payables  6,052 5,167 
   € 14,456 € 14,913 
Total liabilities  € 26,059 € 25,747 
Total equity and liabilities  € 134,601 € 146,071 


Revenue was €1.0 million for the third quarter ending September 30, 2023, compared to €182,000 for third quarter ending September 30, 2022.

Cost of Goods Sold

Cost of goods sold was €336,000 for the three months ending September 30, 2023, representing a gross profit of €640,000, or gross margin of 66.0%. This compares to total cost of goods sold of €63,000 in the third quarter ending September 30, 2022, for a gross profit of €119,000, or gross margin of 65.4%.

Research and Development Expenses

Research and development expenses were €6.6 million for the three months ending September 30, 2023, versus €4.2 million for the prior year period, driven by an acceleration in clinical activities, notably the start of the ACCCESS study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to €5.1 million for the third quarter of 2023, up from €4.8 million in the third quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

Operating Loss

Total operating loss for the third quarter 2023 was €11.0 million versus €8.8 million in the third quarter of 2022. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of September 30, 2023, cash and financial assets totaled €72.5 million, compared to €94.9 million on December 31, 2022. Total cash burn was approximately €4.0 million per month during the third quarter of 2023.

Third Quarter 2023 Report
Nyxoah’s financial report for the third quarter 2023, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q3 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

David DeMartino, Chief Strategy Officer
+1 310 310 1313


  • ENGLISH_Q3 2023 Earnings PR_FINAL

Nyxoah Reports Third Quarter 2023 Financial and Operating Results


Hướng dẫn cách khôi phục mật khẩu Gmail trên điện thoại

Gmail,một trong những ứng dụng dịch vụ email được nhiều người sử dụng rộng rãi nhất hiện nay, ngoài việc phục vụ trao đổi thông tin tài liệu mà còn được dùng làm địa chỉ đăng ký vào nhiều trang web, diễn đàn, Facebook.

Code Phi Đội Mobile, cách nhận và nhập giftcode Phi Đội Mobile

Phi Đội Mobile là thể loại game mới được ra mắt trong tháng vừa qua, Phi Đội Mobile là sự kết hợp giữa Pokemon và thể loại bắn máy bay, và chính vì vừa ra mắt nên không thể thiêu các code Phi Đội Mobile dành cho các

Cách mới để chuyển hình ảnh thành file PDF trên iPhone

Trong thời buổi học online như hiện nay, đôi khi bạn cần gửi hình ảnh bài tập hoặc bài thi dưới dạng file PDF trực tiếp trên iPhone thay vì sử dụng các phần mềm bên thứ ba. Bạn muốn thực hiện chuyển hình ảnh thành file

Cách xử lý khi iPhone hỏng nút nguồn

Nút nguồn trên iPhone hoặc iPad hỏng sẽ rất khó cho người dùng, khi chúng ta không thể khởi động lại thiết bị, tắt máy khi cần thiết.

Tải game Grand Theft Auto V APK MOD bản mới nhất năm 2023

Grand Theft Auto V, hay GTA 5, được biết đến với lối chơi thế giới mở rộng lớn và hoàn toàn tự do với tiềm năng giải trí vô tận. Nó còn được biết đến với chức năng trực tuyến, nơi sự hỗn loạn ngự trị và mỗi nơi người


Đánh giá mainboard MSI Z370 Gaming Pro Carbon AC – Nền tảng mạnh, ép xung linh hoạt

Z370 Gaming Pro Carbon AC được xem là đại diện tiêu biểu cho dòng bo mạch Performance Gaming hướng đến game thủ và người dùng đam mê máy tính. Chính vì vậy mà sản phẩm được MSI ưu ái trang bị đầy đủ tính năng tiên

Trên tay và đánh giá nhanh Huawei Nova 3i vừa ra mắt

Nova 3i sở hữu mặt lưng kính chuyển màu gradient kiểu như Huawei P20 Pro, nhờ thiết kế mặt lưng kính ấn tượng đã đem lại cho máy một thiết kế đẹp măt, hiện đại và tinh tế, với kích thước tổng thể là 157 x 73.7 x 7.3

Combo Strix RX 570 và TUF B450M liệu có đáng tiền?

Khuyến mãi mua ASUS ROG RX 570 Strix tặng TUF B450M – Gaming Plus gần đây của Phong Vũ cũng như của AMD Việt Nam dường như đã làm nguôi đi phần nào nhu cầu xây dựng dàn máy của game thủ. Xét chung về combo này thì bạn